Form 4 for EXEL EXELIXIS, INC.
Accepted 2025-02-28 00:00:00 ET · period of report 2025-02-26 · accession 0000939767-25-000040 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-02-28 | 2025-02-26 | EXEL | Peterson Amy C. | CMO, EVP Prod Dev, Med Aff | A - Grant | $0.00 | +52.2K | 347.1K | +18% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-02-26 | A | A | 52,192 | $0.00 | 347,089 | D | — | — | (F1) Represents shares of Exelixis, Inc. common stock ("Common Stock") that will be issued to the Reporting Person upon vesting of restricted stock units ("RSUs"). Each RSU is the economic equivalent of one share of Common Stock. (F2) The RSUs were granted to the Reporting Person on the Transaction Date pursuant to the Exelixis, Inc. 2017 Equity Incentive Plan. The RSUs will vest as to 1/4th of the original number of shares subject to the RSU award on May 15, 2026 and thereafter as to 1/4th of the original number of shares subject to the RSU award on each May 15th until fully vested. (F3) Includes 314,313 shares of Common Stock that will be issued to the Reporting Person upon vesting of RSUs. |